Skip to main content
MedNextMedNext
Drug ComparisonAminopenicillin

Amoxicillin vs Co-amoxiclav

Clinical Comparison

Clinical Context

Amoxicillin is the first-line aminopenicillin for most community infections. Co-amoxiclav adds clavulanic acid to overcome beta-lactamase resistance, but should be reserved for infections where resistant organisms are likely or the infection is more severe, to support antimicrobial stewardship.

Drug Profiles

Amoxicillin

Aminopenicillin (beta-lactam antibiotic)

Mechanism

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing peptidoglycan cross-linking

Indications

  • Community-acquired pneumonia
  • Acute otitis media
  • Urinary tract infections (uncomplicated)
  • H. pylori eradication
  • Dental abscess
  • Streptococcal pharyngitis

Common Doses

250-500 mg TDS or 1 g TDS for severe infections

Route

Oral, IV

Onset & Duration

Onset 1-2 hours oral; half-life 1 hour

Co-amoxiclav

Aminopenicillin + beta-lactamase inhibitor

Mechanism

Amoxicillin inhibits cell wall synthesis; clavulanic acid irreversibly inhibits bacterial beta-lactamases, restoring amoxicillin activity against resistant organisms

Indications

  • UTIs (complicated)
  • Animal bites
  • Dental infections (severe)
  • Intra-abdominal infections
  • Lower respiratory tract infections when amoxicillin-resistant organisms suspected
  • Diabetic foot infections

Common Doses

375 mg (250/125) or 625 mg (500/125) TDS; IV 1.2 g TDS

Route

Oral, IV

Onset & Duration

Onset 1-2 hours oral; half-life ~1 hour

Key Differences

Spectrum

Amoxicillin

Narrow — many organisms develop resistance via beta-lactamase

Co-amoxiclav

Broader — clavulanate restores activity against beta-lactamase producers

GI side effects

Amoxicillin

Mild diarrhoea

Co-amoxiclav

More diarrhoea and GI upset (clavulanate effect)

Liver toxicity

Amoxicillin

Very rare hepatotoxicity

Co-amoxiclav

Risk of cholestatic jaundice (clavulanate-related)

Bite wounds

Amoxicillin

Not adequate alone for animal/human bites

Co-amoxiclav

First-line for bite wound prophylaxis and treatment

Antimicrobial stewardship

Amoxicillin

Preferred to minimise resistance pressure

Co-amoxiclav

Reserve for cases with confirmed or likely resistance

C. difficile risk

Amoxicillin

Lower risk

Co-amoxiclav

Higher risk due to broader spectrum

Key Advantages

Amoxicillin

  • Narrow spectrum — less disruption to gut flora
  • Very well tolerated
  • Safe in pregnancy
  • First-line for many community infections per NICE
  • Cheap and widely available

Co-amoxiclav

  • Active against beta-lactamase producing organisms (S. aureus, H. influenzae, E. coli)
  • Broader gram-negative and anaerobic cover
  • Reliable for bite wounds and polymicrobial infections
  • IV formulation widely used in hospitals

Key Cautions

Amoxicillin

  • Inactive against beta-lactamase producing organisms
  • Amoxicillin rash (non-allergic) in EBV infection
  • True penicillin allergy — anaphylaxis risk
  • Diarrhoea common
  • Check for penicillin allergy before prescribing

Co-amoxiclav

  • Higher rate of diarrhoea and GI upset than amoxicillin alone
  • Cholestatic jaundice risk (clavulanate-associated, usually reversible)
  • More antibiotic-associated C. difficile risk
  • Avoid if mononucleosis suspected
  • Reserve for when broader spectrum genuinely needed

Clinical Verdict

Start with amoxicillin for uncomplicated community infections (pneumonia, otitis media, UTI). Step up to co-amoxiclav for bite wounds, complicated UTIs, severe dental infections, or when beta-lactamase resistance is suspected.

Medical Disclaimer: This comparison is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making prescribing decisions. Verify all drug information with current clinical guidelines (BNF, NICE, SmPCs).

Full monographs for Amoxicillin & Co-amoxiclav in the MedNext app

Complete dosing, interactions, contraindications, side effects, and more — covering 2,866 drugs with AI-powered search.

Download MedNext Formulary